Retatrutide dosage reference: typical range 0.5 – 12 mg, 1× per week (every 7 days) AM/PM, cycle No strict cycle. Most users transition to a maintenance…
Revolutionary triple agonist targeting GLP-1, GIP, AND glucagon receptors. Phase 3 trials show unprecedented 24%+ weight loss. The next evolution beyond tirzepatide.
Published protocol literature for Retatrutide describes a typical range of 0.5 – 12 mg, dosed 1× per week (every 7 days) am/pm, over a cycle of No strict cycle. Most users transition to a maintenance dose long-term.. Reported half-life: ~6 days.
| Parameter | Reported value |
|---|---|
| Typical dose range | 0.5 – 12 mg |
| Frequency | 1× per week (every 7 days) AM/PM |
| Cycle length | No strict cycle. Most users transition to a maintenance dose long-term. |
| Half-life | ~6 days |
| Route | Subcutaneous injection (most published protocols) |
| Diluent | Bacteriostatic water |
| Commonly stacked with | Conservative stacking recommended due to novelty; may combine with healing peptides like BPC-157 |
Protocols are usually titrated rather than started at the top of the range. The tiers below reflect how Retatrutide dosing is commonly stepped in the published protocol literature.
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Weeks 1 | 0.5 mg | 1×/week | 5 units (5/10/15/20 mg vials) |
| Week 2 | 1 mg | 1×/week | 10 units (5/10/15/20 mg vials) |
| Weeks 3–6 | 2 mg | 1×/week | 20 units (5/10/15/20 mg vials) |
| Weeks 7–10 | 4 mg | 1×/week | 40 units (5/10/15/20 mg vials) |
| Weeks 11–14 | 6 mg | 1×/week | 60 units (10/15/20 mg vials) |
| Weeks 15–18 | 8 mg | 1×/week | 80 units (10/15/20 mg vials) |
| Weeks 19–22 | 10 mg | 1×/week | 100 units (10/15/20 mg vials) |
| Weeks 23+ | 12 mg | 1×/week | 120 units (15/20 mg vials) |
Concentration in mcg/mL equals vial milligrams multiplied by 1000, divided by the millilitres of bacteriostatic water added. Volume per dose in mL equals the target dose in mcg divided by that concentration. On a U-100 insulin syringe, multiply the volume in mL by 100 to read the units.
| Vial | Bacteriostatic water | Resulting concentration |
|---|---|---|
| 5 mg vial | 0.5 mL bacteriostatic water | 10,000 mcg/mL |
| 10 mg vial | 1 mL bacteriostatic water | 10,000 mcg/mL |
| 15 mg vial | 1.5 mL bacteriostatic water | 10,000 mcg/mL |
| 20 mg vial | 2 mL bacteriostatic water | 10,000 mcg/mL |
| State | Conditions | Shelf life |
|---|---|---|
| Lyophilized (Powder) | Refrigerate 2–8°C (36–46°F) or freeze | 12–24 months refrigerated; longer frozen |
| Reconstituted | Refrigerate 2–8°C only; no freezing | 21–30 days typically |
| In Transit | Insulated packaging; ice packs | Minimize time; avoid heat exposure |
| MK-677 (Oral) | Room temp okay; cool/dry preferred | Per manufacturer; typically 12+ months |
Dose ranges on this page summarise published research and practitioner protocol literature for Retatrutide. They are a reference, not medical direction. All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Published protocol literature for Retatrutide generally describes 0.5 – 12 mg, administered 1× per week (every 7 days) am/pm. Individual protocols vary and should be set by a licensed practitioner.
1× per week (every 7 days) AM/PM. Frequency is driven by half-life — Retatrutide has a reported half-life of ~6 days, so shorter-acting compounds are dosed more often.
Typical cycle length reported is No strict cycle. Most users transition to a maintenance dose long-term.. Cycling exists to limit receptor desensitisation and to create assessment windows, not as a fixed rule.
5mg → 0.5ml bacteriostatic water; 10mg → 1ml bacteriostatic water; 15mg → 1.5ml bacteriostatic water; 20mg → 2ml bacteriostatic water. Concentration in mcg/mL equals vial milligrams times 1000 divided by millilitres of bacteriostatic water.
Retatrutide activates three receptors (GLP-1, GIP, glucagon) versus semaglutide's one and tirzepatide's two. The added glucagon arm is thought to increase energy expenditure.
No — as of 2026 it is investigational and in late-stage trials.